...
首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma.
【24h】

Fatal hepatic and renal toxicity as a complication of trabectedin therapy for radiation-induced sarcoma.

机译:致命的肝和肾毒性,是trabectedin治疗放射线肉瘤的并发症。

获取原文
获取原文并翻译 | 示例
           

摘要

Trabectedin therapy was prescribed for a patient with radiation-induced sarcoma. Two doses of trabectedin were given before therapy was discontinued with the patient experiencing renal and liver failure. Despite discontinuing trabectedin the patient continued to experience increases in liver transaminases, bilirubin, blood urea nitrogen, and serum creatinine. Hemodialysis was initiated with no improvement. With all other causes being ruled out, trabectedin likely caused hepatic and renal failure leading to death in this patient. Recent literature suggests that patients may benefit from prophylactic dexamethasone as a means of reducing hepatic toxicity.
机译:特拉贝丁治疗是针对放射线引起的肉瘤的患者。患有肾和肝衰竭的患者中止治疗前,先给予两剂Trabectedin。尽管停用trabectedin,患者的肝转氨酶,胆红素,血尿素氮和血清肌酐仍继续升高。开始进行血液透析没有改善。在排除所有其他原因的情况下,曲贝汀可能引起肝和肾衰竭,导致该患者死亡。最近的文献表明,患者可从预防性地塞米松中获益,以降低肝毒性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号